This document discusses the integration of artificial intelligence (AI) into electronic protocol (eProtocol) design for clinical trials, highlighting its potential to enhance efficiency, adaptability, and patient centricity. Through AI-driven methodologies, clinical trial protocols can become more dynamic and responsive, leading to optimized trial designs and improved patient outcomes. The review examines the transformative impact of AI in drug development, emphasizing its role in personalizing treatment and streamlining healthcare practices.
Related topics: